Background
==========

Increasing rates of sexually transmitted infections (STIs) remain a growing concern worldwide \[[@B1]-[@B3]\]. Despite active and passive surveillance and multiple interventions aimed at increasing the number of cases found and treated, genital chlamydia (CT), gonorrhea (GC) and human papillomavirus (HPV) infections contribute to a large burden on health resources. Strategies to control STIs have included interventions aimed at improving access to screening among individuals who are at high risk of acquiring STIs. Current clinical screening methods for GC and CT involve the collection of cervical (endo- and ecto-), urethral, pharyngeal and rectal swabs. Urine and vaginal specimens are also collected for GC and CT. HPV testing using self-collected vaginal swabs is available but is not publicly funded, and, moreover, clinician-testing for HPV has not been adopted in Canada. Recent publications have identified a need for targeted site-specific screening of the pharynx, urethra and rectum to increase detection of cases, especially in individuals engaging in high risk activities such as men who have sex with men \[[@B4],[@B5]\].

Self-collection of urine, vaginal, rectal and pharyngeal samples provides a different option for screening outside of the traditional clinical setting. Settings for self-collection of samples for STI testing can include community-based organizations, street outreach settings and the internet. However, more evidence is required to determine whether self-collected specimens are as accurate as clinician-collected specimens in terms of diagnostic accuracy for CT, GC and HPV, prior to recommending it as standard practice. The purpose of our systematic review and meta-analysis will be to examine whether a self-collected sample is as accurate as a clinical-collected sample for the diagnosis of CT, GC and HPV. Our specific research question is:

Are self-collected vaginal, urine, pharyngeal and rectal samples as accurate as clinician-collected samples for the diagnosis of CT, GC and HPV?

Methods
=======

Inclusion and exclusion criteria
--------------------------------

Eligible studies will include both randomized and non-randomized controlled trials, pre- and post-test designs, and controlled observational studies examining self-collected versus clinician-collected samples using the nucleic acid amplification test (NAAT) to detect GC, CT and HPV. All manuscripts must include a reference standard of a clinician-collected specimen. Manuscripts that only report a kappa statistic (measuring agreement between the self-collected sample and the clinician-collected sample) will also be reviewed. Table [1](#T1){ref-type="table"} delineates the eligibility guidelines for comparing sites for self-collected sample versus clinician-collected samples. Studies will be excluded when the time period between self- and clinician-collected samples is longer than three weeks because the disease status of the patient may have changed. Other reasons for exclusion are: (a) participants are known to be positive for disease before enrolment in the study, (b) combined test results (for example, self-collected combined urine and vaginal samples) or (c) more than 20% of included patients dropped out of the study.

###### 

Eligibility guidelines for comparing sites for self-collected sample versus clinician-collected samples

                                      **Clinician-collected samples**                         
  ------------------------ ---------- --------------------------------- ---------- ---------- -----
  Self-collected samples   Urine      Eligible                          Not        Eligible   Not
  Rectal                   Not        Eligible                          Not        Not        
  Vaginal                  Eligible   Not                               Eligible   Not        
  Pharyngeal               Not        Not                               Not        Eligible   

Definition of reference standard
--------------------------------

Our reference standard will be clinician-collected samples. Both self-collected and clinician-collected samples must have used a NAAT to be included. NAATs are highly sensitive and specific for the detection of CT and GC when using swabs from the genital tract or first-catch urine specimens \[[@B6]\]. The different NAATs for the detection of CT and GC include: PCR testing (Abbott LCx and Roche COBAS AMPLICOR™ (AC)), strand displacement amplification (Becton Dickinson ProbeTec™ ET), transcription-mediated amplification (Amptima, GenProbe Aptima Combo 2™ (AC2) and the Aptima *Neisseria gonorrhoeae* assay), and the ligase chain reaction (discontinued as of 2002) \[[@B6]-[@B8]\].

Dual assays that test for CT and GC, include AC2, Becton Dickinson ProbeTec™ CT/GC, AC and Abbott Realtime™ CT/NG assays \[[@B8]-[@B10]\]. The GenProbe PACE 2™, discontinued as of December 2012, and the Digene Corporation Hybrid Capture 2™ (HC2) are non-amplified probe tests \[[@B11]\]. HPV NAAT tests in this review will be classified as either HC2 or PCR \[[@B12],[@B13]\]. Table [2](#T2){ref-type="table"} provides the sensitivity and specificity of clinician-collected specimens for GC and CT using NAAT assays.

###### 

Sensitivity and specificity of reference standard (clinician-collected samples) for NAAT tests of gonorrhea and chlamydia

                                          **Vaginal swab**         **Rectal swab**          **Pharyngeal swab**         **Urine**
  ------------------------------------- --------------------- -------------------------- -------------------------- -----------------
  **Gonorrhea**                                                                                                     
   Sensitivity                             96.2 \[[@B13]\]     44-93 \[[@B14],[@B15]\]    60--95 \[[@B14],[@B15]\]   98.9 \[[@B16]\]
   Specificity                             99.3 \[[@B13]\]         99.5 \[[@B15]\]            78.9 \[[@B15]\]        99.3 \[[@B16]\]
  **Chlamydia**                                                                                                     
   Sensitivity                             97.2 \[[@B13]\]     64--94 \[[@B14],[@B15]\]   33--80 \[[@B14],[@B15]\]   96.2 \[[@B16]\]
   Specificity                             95.2 \[[@B13]\]          100 \[[@B5]\]              100 \[[@B5]\]         98.1 \[[@B16]\]
  **Gonorrhea/chlamydia combination**                                                                               
   Sensitivity                             97.2 \[[@B13]\]      100 \[[@B14],[@B15]\]       95 \[[@B14],[@B15]\]     100 \[[@B17]\]
   Specificity                           97--99.4 \[[@B13]\]        98 \[[@B14]\]              98 \[[@B14]\]         98.8 \[[@B17]\]

Search strategy
---------------

Our search will include English and non-English databases. Our search will be limited to articles published since 1990 because of two factors: (a) the HC2 test is the most widely used HPV test worldwide and was first used in 1990 \[[@B14]\] and (b) the oldest currently available NAAT test reported in the literature for self-collected GC or CT was after 1990 \[[@B15]\]. Our search will be conducted on tests that ran between 1990 and June 2013. The databases that will be searched include the Cochrane Database of Systematic Reviews, Web of Science, Database of Abstracts of Reviews of Effects, EMBASE and PubMed/Medline. We have chosen not to register our protocol with PROSPERO.

Search terms
------------

MeSH headings, subject headings and keywords will be created using language that describes laboratory test performances for NAAT tests for GC, CT and HPV. The scope notes of the MeSH headings and subject headings and terms will be reviewed to identify additional terms, common usage and previous usage for terms being searched. Keywords in published journals will also be used. Search terms will include but will not be limited to: internet STI testing; sexually transmitted diseases; sexually transmitted infections; chlamydia; gonorrhea; human papillomavirus/HPV; screening; testing; reproductive health; adolescent health; non-clinic testing; urine testing; vaginal testing; pharyngeal testing; self-collected specimens; home sampling; test performance; test accuracy; PCR, polymerase chain reaction and nucleic acid amplification test sensitivity; specificity and diagnostic ratio. Boolean combinations will be created for more specific searches. Authors will also be asked to identify key articles that should be included in the review. The bibliographies of retrieved articles will also be manually searched as well as key journals such as *Sexually Transmitted Infections*, *Sexually Transmitted Diseases* and *Journal of Clinical Microbiology*.

Data collection
---------------

Data will be abstracted independently by two reviewers using a standardized pre-tested form. Any disagreements between the reviewers will be resolved by a third reviewer. The following data elements will be extracted, and if appropriate, used for stratification if heterogeneity is found: true/false positive; true/false negative; sensitivity; specificity; reference (gold) standard used to compare test characteristics; NAAT platform used; specimen (urine, vaginal, pharyngeal or rectal); diagnostic odds ratio; positive likelihood ratio; negative likelihood ratio; kappa statistic; sex and age of participants; presence of symptoms (if a study includes results from both symptomatic and asymptomatic patients, both sets of results will be included); HIV status; date of study initiation and publication status (published or unpublished); country of study and author affiliation; number of specimens analyzed; number of tests per patient; any elements of blinding; location of self-collection (home, clinic and so on); community type (urban, rural); sex (women, men, transsexual); population type (stable, homeless); sexual orientation (gay, heterosexual, bisexual, transgendered); religion; clinician setting (outreach, primary care, referral); HPV type (high, low or both) and prevalence. If studies involve several self-sampling methods, the first method described will be used in the analysis. We consider any high-risk HPV positive test as standard; however, if the authors have not separated high- and low-risk HPV types, we used their combined data.

Data analysis
-------------

The numbers of true positives, false negatives, false positives and true negatives will be extracted from each study, and test sensitivity and specificity as well as likelihood ratios will be calculated. Coupled forest plots for paired sensitivity and specificity for each study along with 95% confidence intervals will be created in RevMan 5.0 to detect publication bias, if present. A meta-analysis will be conducted according to the Cochrane Collaboration's new recommended methodology for systematic reviews of Diagnostic Test Accuracy \[[@B16]\]. Hierarchical summary receiver operating characteristics (HSROC) analysis will be used, as described by Rutter and Gatsonis \[[@B17]\], as well as a bivariate random effects model for comparison purposes \[[@B18]\]. The HSROC model will be created, using SAS version 19, to provide a general framework for the meta-analysis and to allow for the calculation of the summary receiver operating characteristics (SROC) as well as the expected operating point on the curve and summary estimates of paired sensitivity and specificity (and positive/negative likelihood ratios). The HSROC will also be used to investigate heterogeneity between studies by taking into account both within- and between-study variability. Plots will not be fitted if there are four studies or less, as there will not be enough data to fit the hierarchical models with all five parameters by maximum likelihood. The Q statistic will be used to test for heterogeneity and publication bias will be examined. If heterogeneity is detected then the data will be examined to determine if stratification is appropriate. Studies will be stratified based on sub-grouping from data extraction. If heterogeneity is still evident pooled analyses will not be done and a descriptive summary will be reported.

Quality
-------

Validity will be assessed using the Quadas-2 (Quality Assessment of Diagnostic Accuracy Studies) checklist \[[@B19]\]. Sensitivity analyses will be conducted to investigate the effect of outliers on the summary estimates. The Cochrane Collaboration approach with risk of bias tables will be used to classify the studies as high, low or unclear \[[@B20]\]. The overall risk of bias for an individual study will be categorized as low if the risk of bias is low in all domains, unclear if the risk of bias is unclear in at least one domain without any high risk of bias domains or high if the risk of bias is high in at least one domain. The risk bias assessment will be performed by two reviewers independently and disagreements resolved by consensus.

Discussion
==========

Scoping review
--------------

A search of the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, EMBASE and PubMed/Medline using a review filter was conducted using the terms self-sampling and noninvasive sampling. One previous 2005 systematic review \[[@B21]\] evaluated 29 articles that reported sensitivity and specificity of urine-based NAATs for CT and GC with the specific aim of comparing self-collected urine samples with clinician-collected cervical and urethral samples. They reported congruent test accuracies between self-collection and physician-collected samples for CT, but lower sensitivity for GC in self-collected cervical samples compared to clinician-collected samples. This systematic review lacks information on pooled estimates of rectal or pharyngeal specimens. In addition, this review was published in 2005 and NAAT platforms have since changed significantly, and there are now platforms with greater test performance \[[@B7]\]. Dual assays, which test for both CT and GC, are now available \[[@B8],[@B9]\]. Three other meta-analyses were conducted on the accuracy of self-collected vaginal specimens for diagnosing HPV compared to clinician-collected samples \[[@B22]-[@B24]\]; however, these reviews were conducted prior to 2007 and need updating. Moreover, these reviews did not include the rectum or pharyngeal anatomical sites as collection sites for specimens.

Significance of the review
--------------------------

Increasing rates of STIs remain a growing concern in British Columbia, Canada, and worldwide. Rates of STIs continue to grow despite active and passive surveillance and multiple interventions aimed at increasing the number of cases found and treated. New interventions, such as self-collected sampling, are needed to identify STIs and stop the upward trend.

Reported rates of genital chlamydia (CT) have steadily increased in British Columbia since 1998, from 122/100,000 (1998) to 255/100,000 (2011), with the majority of cases being in females between the ages of 15 and 24 \[[@B2]\]. CT rates for young men in BC have also doubled since 1999 \[[@B1]\]. Similarly, the rate of gonorrhea infections has increased since 1998, from 529 new reported cases in 1998 to 1,573 new cases in 2011 \[[@B1],[@B2]\]. The increased rates of GC and CT heighten concerns of increased rates of pelvic inflammatory disease, and vulnerability to acquiring HIV \[[@B2]\]. In addition, HPV is widespread in Canada and worldwide and persistent infection is correlated with an increased risk of cervical cancer \[[@B25],[@B26]\].

The prevalence of HPV among women aged 13 to 86 is estimated to be 16.8% (with 10.7% being subtype 16 or 18 \[[@B27]\], which are the sub-types that cause 70% of cervical cancers \[[@B28]\]). The prevalence of HPV in men is less clear but cross-sectional studies of men in Vancouver found up to 27% of men have HPV subtype 16 or 18 \[[@B29],[@B30]\].

Barriers to accessing care
--------------------------

Uptake of STI testing remains a public health challenge, with particularly low testing rates among young men (age \< 25) and gay, bisexual and other men who have sex with men (MSM) \[[@B30]-[@B37]\]. Stigma, shame, negative interactions with service providers, concerns about privacy and confidentiality, inaccessible locations, hours of operation, transportation costs and inconvenience have been identified as STI testing barriers \[[@B38]-[@B40]\]. In addition, not having a primary care provider \[[@B36]\] and fear of disclosing risky sexual behaviors to a care provider \[[@B37],[@B41]\] have been shown to be factors that inhibit STI testing in some settings, especially for youths. Strategies to remove barriers to testing have been developed, such as internet-based testing using self-collected samples \[[@B42]-[@B44]\] or community-based screening for hard-to-reach populations \[[@B45],[@B46]\].

Models of internet-based self-sampling
--------------------------------------

A number of models for internet-based testing have been developed, all typically including an online risk self-assessment, test recommendations and specimen collection without requiring presentation to a clinic \[[@B47]\]. Self-collected specimens are taken in a community laboratory or at home \[[@B48]-[@B50]\]. The Clinical Prevention Services Division at the BC Centre for Disease Control is developing an internet-based testing program called *GetCheckedOnline*, aimed at decreasing barriers to STI and HIV testing with an emphasis on youth and MSM. Focus group discussions with youths, MSM and STI clinic clients revealed that they would use the internet-based testing service or recommend it to others \[[@B51]\]. The inclusion of self-collected specimens as part of this program is being considered \[[@B5]\]; however, knowing the accuracy of self-collection specimens compared to clinician-collected specimens for the diagnosis of STIs is required prior to adoption of this program. Ultimately, the goal of internet-based self-sampling programs would be to make screening more accessible, increase the number of people being tested, reduce onward transmission and provide timely treatment.

Cost-effectiveness
------------------

Self-collected samples are also potentially more cost effective compared to clinician-collected samples. Organizing samples through the internet can reduce health service and delivery costs as interventions delivered over the internet are likely to cost less than treatments requiring frequent contact with health-care professionals \[[@B52]\]. Huang and colleagues \[[@B53]\] modelled an internet-based self-sampling chlamydia screening program for young women compared to a clinic-based screening and concluded that the internet-based screening strategy prevented 35.5 more cases of pelvic inflammatory disease and saved an additional US \$41,000 in direct medical costs compared with the clinic-based screening strategy. A similar study found that self-obtained vaginal sampling for chlamydia detection was the least expensive and the most cost-effective method compared to clinician-collected or urine samples, preventing 17 more cases of pelvic inflammatory disease \[[@B54]\]. A third US study found that the lifetime cost of in-home self-collection for detection of high-risk HPV followed by in-clinic cytology triage was slightly lower than clinician-based screening \[[@B55]\].

The outcomes of this systematic review and meta-analysis are important in the detection of STI disease in hard-to-reach populations, in particular, those who may be unwilling to provide samples in traditional settings. The aim of exploring whether self-collected samples have comparable specificity and sensitively to samples collected in traditional settings has the potential to increase testing rates. Presumably, with higher testing levels, transmission could be reduced. Our systematic review will allow patients, clinicians and researchers to determine the diagnostic accuracy of specimens collected by patients compared to those collected by clinicians in the detection of chlamydia, gonorrhea, and HPV.
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